• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

[CORAL-1 trial] Interferon-free regimen for recurrent hepatitis C after liver transplant safe and effective

byTomi JunandXu Gao
November 12, 2014
in Chronic Disease, Gastroenterology, Infectious Disease, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. 33 out of 34 post-liver transplant hepatitis C virus (HCV) patients treated with the trial regimen (ombitasavir, ABT-450/r, dasabuvir, ribavirin) had a sustained virology response at 12 and 24 weeks after the end of treatment.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: HCV-related liver failure is a major indication for liver transplants. However, HCV recurrence after transplant is almost guaranteed and is a major cause of graft failure. Treatment regimens for post-transplant HCV recurrence exist, but are limited by side effects and relatively low response rates.

Recent phase 3 trials (SAPPHIRE I and II, PEARL III and IV, TURQOISE II) have demonstrated the effectiveness of a regimen of ombitasavir, ABT-450/r, dasabuvir and ribavirin (AOD+RBV) for HCV genotype I in a variety of clinical settings. This trial investigated the use of AOD+RBV for treatment of HCV recurrence in the post-transplant population.

AOD+RBV was found to be highly effective and safe, with 33 out of 34 patients having undetectable viral load 12 weeks after the end of treatment. Only one patient discontinued the treatment due to side effects. It should be noted that the treatment regimen does require active management of the dosing of ribavirin and of the patients’ immunosuppressive drugs. Monitoring and management may not be as stringent outside of the trial setting.

Click to read the study, published today in NEJM

RELATED REPORTS

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

Liver transplantation plus chemotherapy improves survival in patients with unresectable colorectal liver metastases

The Scan by 2 Minute Medicine®: The Sound of Music, The Rise of a Promising Alzheimer’s Treatment, Pediatric Liver Transplant, A Heart-shaped Rash

Relevant Reading: Therapy of Hepatitis C — Back to the Future

In-Depth [ randomized controlled trial]: This study enrolled 34 patients from centers in the US and Spain with HCV genotype 1 infection and who had received a liver transplant in the previous 12 months for chronic HCV infection. Exclusion criteria included co-infection with HIV or hepatitis B virus or multi-organ transplantation. The patients were predominantly white males.

The treatment regimen consisted of: ombitasavir, a NS5A inhibitor; dasabuvir, a nonnucleoside NS5B polymerase inhibitor; ABT-450/r, a protease inhibitor boosted with ritonavir to prolong its availability; and ritonavir. Initial dosing of ribavirin and subsequent changes were determined by investigators for each patient. 19 patients had their doses of ribavirin changed; 9 had their doses changed for anemia (a common side effect of ribavirin). 5 patients required erythropoietin due to low hemoglobin levels.

More from this author: Early risk factor for progression of cystic fibrosis identified, Gut microbes implicated in stroke and heart attacks: new dietary link, New leukemia mutation offers therapeutic targets, Childhood ADHD associated with increased risk of suicide, A marker of aggressive liver cancer and potential therapeutic target identified

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: Dasabuvirhepatitis Cinterferonliver transplantombitasavirribavirintransplant surgery
Previous Post

Limiting duration of overseas deployment may prevent mental health problems

Next Post

Morbid obesity increases risk for cervical cancer death

RelatedReports

Study lends support for interferon-free treatment of hepatitis C
2 Minute Medicine

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

November 29, 2024
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Liver transplantation plus chemotherapy improves survival in patients with unresectable colorectal liver metastases

October 8, 2024
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Sound of Music, The Rise of a Promising Alzheimer’s Treatment, Pediatric Liver Transplant, A Heart-shaped Rash

February 20, 2024
Spleen elastography may be effective in the diagnosis of portal hypertension
Gastroenterology

Deep learning algorithm enables accurate and fair prediction of post-liver transplant risk factors

January 17, 2024
Next Post
Rate of weight loss may not affect long-term weight control

Morbid obesity increases risk for cervical cancer death

Remote ischemic preconditioning reduced myocardial injury in CABG patients

Key mutations may protect against coronary artery disease

Number of lives saved due to tobacco control continues to rise

Smokers' support for plain tobacco packaging linked to desire to quit

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.